GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genelux Corp (NAS:GNLX) » Definitions » Cash Flow from Investing

Genelux (Genelux) Cash Flow from Investing : $-16.31 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Genelux Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Genelux spent $0.03 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $3.16 Mil on purchasing investments. It gained $1.50 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Genelux spent $1.69 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Genelux Cash Flow from Investing Historical Data

The historical data trend for Genelux's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genelux Cash Flow from Investing Chart

Genelux Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
-0.02 - -0.05 -14.72

Genelux Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.11 -0.40 -0.28 -13.94 -1.69

Genelux Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Genelux's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Genelux's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genelux  (NAS:GNLX) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Genelux's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $-0.03 Mil. It means Genelux spent $0.03 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Genelux's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Genelux gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Genelux's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Genelux spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Genelux's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Genelux gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Genelux's purchase of investment for the three months ended in Mar. 2024 was $-3.16 Mil. It means Genelux spent {stock_data.stock.currency_symbol}}3.16 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Genelux's sale of investment for the three months ended in Mar. 2024 was $1.50 Mil. It means Genelux gained $1.50 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Genelux's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means Genelux paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Genelux's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means Genelux paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Genelux's cash from other investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means Genelux paid $0.00 Mil for other investing activities.


Genelux Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Genelux's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Genelux (Genelux) Business Description

Traded in Other Exchanges
N/A
Address
2625 Townsgate Road, Suite 230, Westlake Village, CA, USA, 91361
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
Executives
Tony Yu officer: VP, Clinical Trial Operations C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
James L Tyree director 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
John Thomas director C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Aladar Szalay 10 percent owner C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Sean Ryder officer: General Counsel C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
John W Smither director C/O KYTHERA BIOPHARMACEUTICALS, INC., 27200 WEST AGOURA ROAD, SUITE 200, CALABASAS CA 91301
Lourie S. Zak officer: Chief Financial Officer C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Thomas Zindrick director, officer: President and CEO C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE. 230, WESTLAKE VILLAGE CA 91361
Joseph Cappello officer: VP, Pharmaceutical Development C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Doug Samuelson officer: Chief Financial Officer C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE 230, WESTLAKE VILLAGE CA 91361
Caroline Jewett officer: Head of Quality C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE 230, WESTLAKE VILLAGE CA 91361
Ralph Smalling officer: Head of Regulatory C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE 230, WESTLAKE VILLAGE CA 91361
Qian Zhang officer: Associate VP, Research C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Mary Mirabelli director C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Paul Scigalla officer: Chief Medical Officer C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361

Genelux (Genelux) Headlines

From GuruFocus

Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023

By sperokesalga sperokesalga 03-23-2023

Genelux Corporation Announces $33 Million Private Placement

By sperokesalga sperokesalga 05-15-2023

Genelux Corporation Announces Pricing of Initial Public Offering

By GlobeNewswire GlobeNewswire 01-26-2023

Genelux Corporation Announces $18 Million Private Placement

By sperokesalga sperokesalga 06-12-2023

Genelux Corporation Announces Pricing of Initial Public Offering

By Stock market mentor Stock market mentor 01-26-2023